Sector News

Lars Dreiøe joins Sobi as Senior VP, Chief Quality & Compliance Officer

December 22, 2015
Life sciences

Swedish Orphan Biovitrum AB (Sobi) today announced that Lars Dreiøe has been appointed Senior Vice President Chief Quality & Compliance Officer (CQCO). Lars Dreiøe joins Sobi from global pharmaceutical company ALK in Denmark where he has been International Head of Quality.

Lars brings 20 years of experience in the Biotech and Pharmaceutical industry in the Quality, Manufacturing, Product Safety and Regulatory Affairs areas.

“We are delighted to welcome Lars to Sobi”, said Geoffrey McDonough, President and CEO at Sobi. “Sobi has been expanding the scope and geographic area of operations and the demands and complexity of external regulations governing our business has also increased. Lars will sustain and deepen our global commitment to quality in all aspects of our work, and will be a valuable addition to our senior leadership team.”

“I’m very much looking forward to joining the team at Sobi and to entering my new role – developing and delivering therapies at the highest level of quality to people living with a rare disease,” said Lars Dreiøe.

Lars will join Sobi on 18 January 2016.

Source: Swedish Orphan Biovitrum AB

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend